← FDA DRUG APPROVALS

FDA ANDA · ANDA074344

CIMETIDINE HYDROCHLORIDE

Sponsor: HOSPIRA

APPLICATION
ANDA074344
TYPE
ANDA
ORIGINAL APPROVAL
1995-01-31
LATEST ACTION
2002-10-25
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CIMETIDINE HYDROCHLORIDEDiscontinued
CIMETIDINE HYDROCHLORIDE EQ 300MG BASE/2ML · INJECTABLE · INJECTION

Approval history

2002-10-25Manufacturing (CMC) · Supplement 10AP
2001-03-22Manufacturing (CMC) · Supplement 8AP
2001-03-22Manufacturing (CMC) · Supplement 9AP
2000-01-07Labeling · Supplement 7AP
2000-01-07Manufacturing (CMC) · Supplement 6AP
1996-10-03Manufacturing (CMC) · Supplement 4AP
1996-07-26Labeling · Supplement 5AP
1995-12-22Labeling · Supplement 2AP
1995-01-31OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →